Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,633 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ADHERE Clear all
Terminated Phase 1Phase 2 Interventional

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

NCT01929954
View directory record Official record
Conditions
Edentulous Alveolar Ridge
Interventions
Gintuit, Bio-Gide
Biological · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 5, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254
View directory record Official record
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 5, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

NCT07464951
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
Biological · Drug
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 5, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

NCT03809533
View directory record Official record
Conditions
Kidney Transplantation, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Amit D Tevar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

NCT05683249
View directory record Official record
Conditions
ADHD
Interventions
NRCT-101-SR, Placebo
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 5, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Doravirine, 2 NRTIs, DOR/3TC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
4 Weeks to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 5, 2026, 9:03 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity Modifies Exercise Responsiveness

NCT07792967
View directory record Official record
Conditions
Multimorbidity
Interventions
SLIMM - Sit less, interact, move more, PB125
Behavioral · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 9:03 PM EDT
Terminated Phase 3 Interventional

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

NCT00134264
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 75 Years
Enrollment
15,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 5, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

NCT06866964
View directory record Official record
Conditions
Germ Cell Tumor, Testicular Cancer
Interventions
Low-dose ASA
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5

NCT00112125
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
OPTIMIZER System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 5, 2026, 9:03 PM EDT
Terminated Phase 4 Interventional Results available

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

NCT05278858
View directory record Official record
Conditions
Alopecia Areata
Interventions
MedJet Device with intralesional triamcinolone
Combination Product
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 5, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

NCT06008938
View directory record Official record
Conditions
Hemophilia B
Interventions
HEMGENIX, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

NCT00808093
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GSK256073
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

In Vivo Dosimetry During Prostate Cancer Radiotherapy

NCT01307852
View directory record Official record
Conditions
Prostate Disease
Interventions
Plastic Scintillation Detectors
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT06517485
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma
Interventions
upifitamab rilsodotin
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 5, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

NCT04711915
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

NCT02107235
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
oral rigosertib, cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Aurora, Colorado • Newark, Delaware • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

NCT05437120
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Los

NCT06079658
View directory record Official record
Conditions
Obesity
Interventions
Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss
Behavioral
Lead sponsor
Coastal Carolina University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Conway, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

NCT00948935
View directory record Official record
Conditions
Biliary Cancer, Cholangiocarcinoma
Interventions
Gemcitabine, Irinotecan, Panitumumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 5, 2026, 9:03 PM EDT
Withdrawn Phase 1Phase 2 Interventional

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

NCT01188889
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
RAD001, Imatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

NCT00534378
View directory record Official record
Conditions
Seizures
Interventions
Midazolam
Drug
Lead sponsor
U.S. Army Office of the Surgeon General
Federal
Eligibility
18 Years to 54 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2007 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Different Add Powers on the Comfort and Productivity of Computer Users With Fixed or Free Head Movement

NCT00317525
View directory record Official record
Conditions
Refractive Errors, Asthenopia
Interventions
Spectacle Lenses
Device
Lead sponsor
American Optometric Association
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Sep 5, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

NCT03512210
View directory record Official record
Conditions
Hepatitis C, HIV-1-infection, Liver Diseases
Interventions
Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy
Drug · Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 5, 2026, 9:03 PM EDT